Whitehawk Therapeutics shareholders approve director slate, executive pay at annual meeting

Filed June 12, 2026 · Period ending June 11, 2026 · ~1 min read

Key Changes

• low

  Shareholders elected three Class III directors (Behzad Aghazadeh, Richard Maroun, Emma Reeve) to serve three-year terms through 2029, with 82% of voting shares represented at the meeting.

  Item 5.07 verify on EDGAR →
• low

  Executive compensation received advisory approval from shareholders in non-binding say-on-pay vote.

  Item 5.07 verify on EDGAR →
• low

  BDO USA ratified as independent auditor for fiscal year 2026.

  Item 5.07 verify on EDGAR →